CASP1 and systemic sclerosis: Our data demonstrated that caspase-1 activity was also increased in ASSD patients (1.25 RFU (IQR: 1.15–1.35 RFU)) (Figure 1E), compared to the group of SSc patients (0.75 RFU (IQR: 0.62–1.14 RFU)).